What Kisunla is
Kisunla (donanemab) received full traditional FDA approval in July 2024. Like Leqembi, it is an anti-amyloid therapy: it targets the beta-amyloid plaque that builds up in the brain in Alzheimer's disease, with the goal of slowing progression in people with early symptomatic disease.
Its approval gives neurologists and neurocognitive specialists a second proactive option for treating and slowing the progression of Alzheimer's disease.
Who may be eligible
Kisunla is for early symptomatic Alzheimer's disease, including mild cognitive impairment due to Alzheimer's. As with Leqembi, your care team first confirms amyloid in the brain, reviews your health history and imaging, and determines with you whether treatment is appropriate.
How treatment works
Kisunla is given as an IV infusion once every four weeks. Your care team monitors treatment closely, including periodic MRI scans. Your provider will explain the schedule, monitoring, and the risks and benefits for your specific situation, and answer your family's questions in plain language.
If you are comparing Leqembi and Kisunla, that is exactly the conversation to have with a neurocognitive specialist. The right answer depends on your diagnosis, your imaging, your health history, and your preferences.
This guide is for education and is not medical advice. Treatment decisions are made with your provider after a full evaluation.